Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 12, 2016. The document serves as a transaction notification regarding a specific executive compensation event rather than a comprehensive financial report.
Key Financial Metrics
The filing does not provide aggregate financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It details a single transaction involving the Company Secretary:
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Transaction Type: Cash payment following the vesting of 25% of a Deferred Investment Award Plan made on July 8, 2010.
- Price: £16.4525 per ordinary share.
- Volume: 4,034.1312 notional ordinary shares.
- Date of Transaction: July 8, 2016.
Material Changes
The filing does not report material changes to the company's financial position or operations compared to prior periods. It solely documents the settlement of a deferred investment award for Mrs. V. A. Whyte.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is a regulatory disclosure of a specific personnel transaction.
Key Facts for Investor Verification
- Verify the vesting schedule and terms of the GlaxoSmithKline Deferred Investment Award Plan referenced in the transaction.
- Confirm the share price of £16.4525 against market data for July 8, 2016, to ensure accurate valuation of the notional shares.
- Note that this filing does not impact the company's consolidated financial statements significantly due to the isolated nature of the transaction.